How the Endocannabinoid System Affects Liver Disease
The endocannabinoid system plays contrasting roles in liver disease: CB1 receptor activation promotes fibrosis, steatosis, and cancer progression, while CB2 activation inhibits fibrosis, suggesting targeted cannabinoid therapy could benefit liver patients.
Quick Facts
What This Study Found
CB1 receptor stimulation increases fibrosis and inflammatory activity by stimulating stellate cells and may promote liver steatosis and carcinogenesis. CB2 receptor activation inhibits fibrosis. In end-stage liver disease, the endocannabinoid system contributes to encephalopathy, portal hypertension, splanchnic vasodilatation, and cirrhotic cardiomyopathy.
Key Numbers
CB1 and CB2 receptors expressed in myofibroblasts and liver endothelial cells; expression elevated in chronic liver disease
How They Did This
Review of the endocannabinoid system's role in chronic liver diseases, examining CB1 and CB2 receptor expression and function in liver cells.
Why This Research Matters
Understanding the opposing roles of CB1 and CB2 receptors in liver disease opens the door to targeted cannabinoid therapies that could inhibit fibrosis (via CB2) without promoting it (via CB1). This has implications for the millions of people with chronic liver disease worldwide.
The Bigger Picture
The endocannabinoid system's dual role in liver disease represents both a risk (CB1-mediated fibrosis) and opportunity (CB2-mediated protection). Selective CB2 agonists could potentially become a new class of liver-protective drugs.
What This Study Doesn't Tell Us
Review article without new clinical data. The translation from receptor-level understanding to clinical treatments faces many hurdles. Most evidence is preclinical.
Questions This Raises
- ?Could selective CB2 agonists become treatments for liver fibrosis?
- ?Should cannabis users with chronic liver disease be concerned about CB1-mediated effects?
Trust & Context
- Key Stat:
- CB1 promotes liver fibrosis while CB2 inhibits it
- Evidence Grade:
- Review of preclinical and clinical literature. Conceptually important but no new data presented.
- Study Age:
- Published in 2024.
- Original Title:
- Cannabinoids and the endocannabinoid system in liver diseases.
- Published In:
- Clinical and experimental hepatology, 10(4), 211-217 (2024)
- Authors:
- Parfieniuk-Kowerda, Anna, Martonik, Diana, Andrzejuk, Aleksandra, Tarasik, Aleksander, Flisiak, Robert
- Database ID:
- RTHC-05606
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is cannabis bad for the liver?
It depends on which cannabinoid receptors are activated. CB1 activation can promote fibrosis and fatty liver, while CB2 activation can protect against fibrosis.
Could cannabinoids treat liver disease?
Selective CB2 receptor agonists show theoretical promise for reducing liver fibrosis, but clinical treatments have not yet been developed.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05606APA
Parfieniuk-Kowerda, Anna; Martonik, Diana; Andrzejuk, Aleksandra; Tarasik, Aleksander; Flisiak, Robert. (2024). Cannabinoids and the endocannabinoid system in liver diseases.. Clinical and experimental hepatology, 10(4), 211-217. https://doi.org/10.5114/ceh.2024.145358
MLA
Parfieniuk-Kowerda, Anna, et al. "Cannabinoids and the endocannabinoid system in liver diseases.." Clinical and experimental hepatology, 2024. https://doi.org/10.5114/ceh.2024.145358
RethinkTHC
RethinkTHC Research Database. "Cannabinoids and the endocannabinoid system in liver disease..." RTHC-05606. Retrieved from https://rethinkthc.com/research/parfieniuk-kowerda-2024-cannabinoids-and-the-endocannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.